Get Reimbursed in
Canada Fast

We embed as your commercial team until your novel drug or AI-health product secures CADTH/pCPA approval and first institutional contracts.

Book a Call

Accelerate Market Entry

Strategic Growth AI accelerates market entry for life sciences and AI-health companies, reducing failure risk by up to 60 percentage points and driving faster revenue.

We’re seasoned operators who align regulatory, reimbursement, and GTM strategies through our SGAI Clarity Intelligence™ platform, embedded expertise, and partner network.

Faster launches. Investor-grade execution.

Real-world traction.

Market Entry & Expansion Services

At Strategic Growth AI, our interconnected services guide life sciences and AI-health innovators through North American market entry, from early decision modeling and fundraising to regulatory prep, pilots, launch execution, and post-launch optimization.

Tailored for pharmaceuticals, biotech, diagnostics, medtech, and digital health, we deliver end-to-end support. What sets us apart? We're not just advisors, we're AI-powered operators who've scaled ventures firsthand, slashing failure risks by up to 60 percentage points with proprietary tools like SGAI Clarity™, milestone-driven execution, and a vast partner network for faster revenue and real traction.

Explore Solutions →

Market Entry & Expansion

Commercialization De-Risking

SGAI Clarity Intelligence™

Interim Leadership

Payer Aligned GTM

Investor-Grade Decision Tools

Market Entry &

Expansion Services

Pilot Projects

AI Integration

Post Launch Optimization

Fund Raising & Partner Brokering

Shorten Time to Market & Save Money

Benefits

Our sequenced services deliver up to 60 percentage points in risk reduction, 10-30% faster paid claims, and investor-grade execution.

Here's how we drive your success:

1. Start Strong with Investor-Grade Decision Tools

Assess viability amid $236B patent cliffs, perfect for biotech firms modeling ROI before committing capital

2. Secure Funding Fast via Fundraising & Partner Brokering

Tap CVCs and grants like NRC-IRAP, fueling 77% expected M&A surges for diagnostics startups needing quick alliances

3. Build Your Roadmap with Market Entry & Expansion

Navigate U.S./Canada regs and localization, compressing timelines for medtech devices entering competitive sectors

4. De-Risk Early with Commercialization De-Risking

Kill/pivot/scale frameworks address 40% post-entry failures, safeguarding AI-health ventures from costly pivots

5. Benchmark Evidence via SGAI Clarity Intelligence™

Align with payer/RWE standards under FDA 2025 guidelines, accelerating approvals for SaMD and imaging tools

6. Enhance Products with AI Integration

Embed gen AI for RWE synthesis, boosting 60% of exec investments in launches, ideal for digital health optimizing real-time data

7. Win Reimbursement with Payer Aligned GTM

Craft PMF strategies for CMS/CADTH, meeting RWE demands to speed revenue for pharma molecules

8. Validate Real-World with Pilot Projects

Run 3-6 month betas to counter 95% AI pilot failures, generating proof for diagnostics in Canadian systems

9. Execute Seamlessly with Interim Leadership

Embed operators for milestone-driven rollouts, per best practices, scaling medtech teams efficiently

10. Sustain Growth with Post-Launch Monitoring

AI dashboards optimize uptake, tackling 80% zero-ROI AI initiatives for long-term traction in all sectors

Insights Pulse

Major Shifts in Life Sciences for 2025

The life sciences sector, spanning pharma, biotech, medtech, and diagnostics is experiencing rapid change in 2025. Valued at nearly $2 trillion globally, the industry continues to expand thanks to breakthroughs in oncology, immunology, and metabolic health. Yet it’s a year defined by both innovation and disruption: inflation, patent cliffs, and regulatory volatility are now daily realities. Still, 75% of industry leaders remain optimistic, seeing these headwinds as catalysts

Clarity Under Constraint: How We Help Clients Prioritize Their Next Expansion Channel

At Strategic Growth AI, we help regulated innovators turn commercialization chaos into clarity, especially when capital, bandwidth, and compliance all constrain the options. One of the structured tools we use is the weighted decision matrix , part of our broader Clarity Under Constraint™ methodology. This approach is designed to help founders and executive teams make evidence-led, high-confidence decisions under pressure. Example - The Challenge: Multiple Good Options, No Co

Pilot to Paid: Cut Risk by up to 60 pp and 2x Milestone Success

Health Tech's Execution Gap Is Costing You Millions. We Built a Model That Fixes It. Despite record funding and breakthrough innovation, over 70% of health tech launches stall after pilots—failing to convert proof into payer-backed adoption, scale, or sustainable revenue. [Sources: McKinsey, Exploding Topics, Failory, HealthTech Index 2025] At Strategic Growth AI, we’ve spent the last eight months analyzing why these failures happen—then building the model to prevent them. We

Proof

Based on PDM™ Monte Carlo projections and industry benchmarks. Actual outcomes may vary.

60 pp

Lower Failure Risk

15 - 35%

Smarter Resource Use

10 - 30 %

Faster to Paid Claims

1.5 - 2.3x

Milestone Success

Explore Proof →

Who We Serve

Investors & Funds

Companies & Ventures

view page

Sectors

Pharmaceuticals & Biotech

AI / Digital Health & SaMD

Diagnostics & Imaging

Medical Devices & Medtech

view page

International Market Entry

We help companies enter and scale in Canada, the U.S. and other markets. Our operator‑led team integrates AI, regulatory, reimbursement and market‑access expertise, to de‑risk expansion and accelerate adoption.

Services include preparing your product and evidence for U.S., Canadian and global regulatory requirements, crafting go‑to‑market plans and using investor‑grade scenario modelling to prioritize capital and scale efficiently.

Learn more →